AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management

Active, not recruitingOBSERVATIONAL
Enrollment

20,000

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

March 27, 2026

Study Completion Date

March 27, 2030

Conditions
Coronary Artery Disease
Interventions
DIAGNOSTIC_TEST

AI-enabled quantitative coronary plaque analysis (AI-QCPA)

The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.

Trial Locations (1)

27401

Moses Cone Memorial Hospital, Greensboro

Sponsors

Lead Sponsor

All Listed Sponsors
lead

HeartFlow, Inc.

INDUSTRY